Matthias Wolfl

TL;DR: It is demonstrated that immature DC, harvested on days 9 to 11 and exposed to IL-10 for the last 2 days of culture, show a strongly reduced capacity to stimulate a CD4+ T cell response in an allogeneic MLR in a dose-dependent manner, and data suggest thatIL-10 converts immature DC into tolerogenic APC, which might be a useful tool in the therapy of patients with autoimmune or allergic diseases.

TL;DR: In vitro priming of naive T cells from healthy donors to Wilms tumor antigen 1 (WT1), a protein overexpressed in various malignancies, appears to be an efficient and sensitive in vitro technique to rapidly identify and isolate antigen-specific CD8(+) T cells present at low frequencies and displaying heterogeneous functional profiles.

TL;DR: A way to harness the power of the donors’ immune cells against some leukemias, without triggering GVHD in the bone marrow recipients is reported, supporting the idea that WT1 targeting is specific to the tumor cells and safe for patient use.

TL;DR: Using these techniques, high-avidity CTL clones specific for an A()0201-restricted epitope of WT1 have been generated from nearly all normal A2(+) donors tested, and will soon be tested for therapeutic activity in clinical trials of adoptive immunotherapy in patients with relapsed leukemia after transplantation.

TL;DR: It is demonstrated that a known in vivo HCV mutation involving a TCR contact residue significantly diminishes T cell recognition and, in contrast to the original sequence, fails to effectively prime naive T cells.